AYTU BioPharma, Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2023, compared with the three months ended September 30, 2022. This is the company’s fiscal first quarter of 2024; the request metadata labels it 2023 Q1. Unless stated otherwise, financial amounts below are in U.S. dollars.
Business context
Aytu commercializes prescription products through its Rx segment and consumer healthcare products through its Consumer Health segment. Its Rx portfolio includes ADHD products Adzenys XR-ODT and Cotempla XR-ODT, plus pediatric products. Management is prioritizing revenue-generating commercial products and plans to wind down or monetize the Consumer Health segment during fiscal 2024.
Financial results and liquidity
| Metric | Quarter ended Sep. 30, 2023 | Quarter ended Sep. 30, 2022 |
|---|---|---|
| Net revenue | $22.1 million | $27.7 million |
| Gross profit | $14.8 million | $18.0 million |
| Gross margin | 67% | 65% |
| Operating loss | $1.5 million | $1.8 million |
| Net loss | $8.1 million | $0.7 million |
| Net loss per share | $1.48 | $0.28 |
| Cash used in operating activities | $0.2 million | $9.1 million |
Revenue fell 20%. Rx revenue declined to $17.8 million from $18.7 million, while Consumer Health revenue fell to $4.3 million from $9.0 million. Within Rx, ADHD portfolio revenue rose to $15.1 million from $11.6 million, partly offsetting lower pediatric portfolio revenue, which was $2.6 million versus $6.6 million. The gross margin percentage improved, although gross profit dollars decreased.
The net loss increase mainly reflects a $5.9 million non-cash loss from revaluing derivative warrant liabilities; the prior-year quarter recorded a $2.2 million gain. The company reported $0.7 million of other expense, including interest and other items.
At September 30, cash and cash equivalents were $20.0 million, accounts receivable $29.9 million, and current assets $70.6 million against current liabilities of $65.5 million. Total liabilities were $100.7 million and stockholders’ equity $32.2 million. Debt included a $15.0 million Avenue term loan, due January 2025, and $1.2 million outstanding on the revolving line; carrying value of total debt was $14.9 million. Cash declined $3.0 million during the quarter, to $20.0 million.
Changes, outlook and key risks
- Operating expenses declined to $16.3 million from $19.8 million, including lower advertising and direct marketing, general and administrative, and research and development costs. Management expects R&D expense to fall further as the company focuses on commercial operations.
- Management says suspension of clinical development programs is expected to save more than $20 million in projected study costs over the next three fiscal years. Healight was terminated and NT0502 rights were returned; AR101 development remains suspended.
- The company received $3.8 million from the Employee Retention Credit program during the quarter. It recorded the amount as a liability pending regulatory audit or further IRS clarification; a $0.4 million vendor fee was expensed.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern. It states that available working capital is insufficient to fund planned operations for the 12 months following the filing, citing obligations that may become due, particularly the Avenue Note. Mitigation plans include improving operating cash flow, winding down or monetizing Consumer Health, refinancing the note, and potentially raising capital or monetizing assets. Success is not assured.
- The Avenue Note carries an effective interest rate of 19.6%; the company says it was in compliance with covenants on both the Avenue facility and Eclipse line at September 30. The company expects to refinance the Avenue Note if cash is insufficient to repay it at maturity.
- Inflation and supply-chain disruptions may continue through fiscal 2024. No specific numerical revenue, earnings, or cash-flow guidance is provided.
- Disclosure controls were deemed ineffective due to material weaknesses in accounting for complex warrants and inventory valuation. Management and the Audit Committee described remediation measures; the weaknesses were not considered remediated.
- Legal matters include a shareholder derivative suit with a proposed settlement subject to court approval, a Sabby/Walleye warrant dispute settled in October 2023, and a former employee case that remains pending. The company says the employee case’s financial impact cannot currently be predicted.
Filing inconsistency: The MD&A states that gross profit increased 2%, but the financial statements report gross profit of $14.8 million versus $18.0 million, a decrease. Investors should verify this discrepancy against the filed statements and any subsequent clarification.
Important facts for investors to verify
- Whether Aytu can refinance or otherwise meet the $15.0 million Avenue Note maturity in January 2025, and its ability to maintain liquidity before then.
- The timing, costs, and proceeds, if any, from winding down or monetizing the Consumer Health segment.
- Revenue trends in the ADHD and pediatric portfolios and the reasons for the continued decline in Consumer Health sales.
- The status and financial treatment of the $3.8 million Employee Retention Credit, including any audit or repayment exposure.
- Progress in remediating warrant-accounting and inventory-valuation control weaknesses, and the gross-profit inconsistency noted above.
- Potential dilution and earnings volatility from derivative warrant liabilities and outstanding warrants.